Poor
Partial Alignment
Patient Risk:
Medium
Summary
The AI response contains largely plausible label-consistent statements for the CrCl > 95 mL/min limitation and premature discontinuation risk, but it also includes unsupported and unverifiable conclusions and does not meet the required standard for FDA-label compliance verification using only the provided label excerpts. Several other requested label elements (dosage specifics, missed dose instructions, NVAF dose-reduction triggers, DVT/PE regimens, administration/transition guidance, and full interaction/precaution details) were not actually evaluated against the supplied text.
Category Scores
Accurate Statements
Premature discontinuation of any oral anticoagulant without adequate alternative anticoagulation increases the risk of ischemic events (boxed warning B / warning 5.2).
Boxed Warning B and 5.2 (premature discontinuation risk; consider coverage with another anticoagulant if discontinued for reasons other than pathological bleeding or completion of a course)
SAVAYSA should not be used in NVAF patients with CrCl > 95 mL/min due to increased ischemic stroke risk vs warfarin (boxed warning A / limitation of use / warnings 5.1 / clinical studies 14.1 / dosage 2.1).
Boxed Warning A; 1.1 Limitation of Use for NVAF; 2.1; 5.1; 14.1 (all explicitly state not to use in CrCl > 95 mL/min and increased ischemic stroke vs warfarin)
Unsupported Statements
The AI evaluation states it is 'supported' and then recommends 'Do not accept supported as-is' due to missing verification, but still categorizes overall as supported earlier; the approach mixes claims of support with non-verification without providing a complete audit against all provided claims.
The response does not perform a systematic claim-by-claim alignment for all user-provided claims; it only supports two boxed-warning-related ideas and leaves the remainder effectively unverified against the excerpts provided.
The AI lists 'supported_claims' for two specific statements, but the overall output does not confirm alignment for the majority of the user’s listed claims (e.g., NVAF dose-reduction triggers, missed-dose guidance, DVT/PE dosing with continuation after initial therapy, transition guidance, monitoring for spinal/epidural hematoma, and interaction-driven dosing/pausing decisions).
Those claims are not evaluated using the supplied label excerpts; therefore they are not shown to be supported by the provided text.
Contradictions
Important Omissions
Claim-by-claim assessment of the majority of the user's listed assertions (e.g., NVAF dose-reduction criteria and specific triggers, missed dose instructions, DVT/PE dosing regimen tied to continuation after initial therapy, how label fits with prior anticoagulant treatment/transition guidance, and detailed interaction-driven management/pausing/different anticoagulant approach).
Importance:
High
Any explicit alignment scoring against dosage and administration claims beyond the limited CrCl > 95 mL/min restriction and premature discontinuation warning.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Misclassification of overall label alignment without verifying many dosing/administration-related claims could lead to incomplete or incorrect interpretation of label requirements. The two core boxed-warning elements cited are supported, but insufficient coverage of other safety-critical label areas is present.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partial Alignment
Primary Issue
The response does not complete a comprehensive, claim-by-claim FDA-label alignment for the full set of user-provided dosing/administration/interaction/transition claims; it only provides verified support for two boxed-warning-related statements.
Suggested Improvement
Re-run the audit for each of the user's listed claims using only the supplied label excerpts (or provide additional exact FDA-label text for the missing sections), and output a structured supported/unsupported/contradicted/omitted determination per claim.